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Abstract
Objective: This study investigated the effects of Ulinastatin (UTI) and docataxel (Taxotere, TAX) on tumor growth
and expression of interleukin-6 (IL-6), interleukin-8 (IL-8), and tumor necrosis factor-a (TNF-a) in breast cancer.
Methods: MDA-MB-231 human breast carcinoma cells were cultured in vitro and injected into nude mice to
establish breast tumor xenografts in vivo. Cultured cells and mice with tumors were randomly divided into four
groups for treatment with TAX, UTI, and TAX+UTI. The effects of these drug treatments on cell proliferation and
apoptosis was measured using the MTT assay and the Annexin V/propidium iodide (PI) double-staining method,
respectively. IL-6, IL-8, and TNF-a expression levels were determined by measuring mRNA transcripts in cultured
cells by RT-PCR and cytokine proteins in solid tumors using immunohistochemistry.
Results: UTI, TAX, and UTI+TAX inhibited the growth of MDA-MB-231 cells in vitro and tumors in vivo. These two
drugs, particularly when used in combination, promote tumor cell apoptosis and down-regulate the expression
IL-6, IL-8, and TNF-a cytokines.
Conclusion: Both UTI and TAX inhibited the growth of MDA-MB-231 breast carcinoma cells. UTI enhanced the
inhibitory effect of TAX by a mechanism consistent with the down-regulated expression of IL-6, IL-8, and TNF-a.
Backgroud
Along with the increasing incidence of breast cancer
tumors, which now account for 18% of all female
tumors, 1.2 million women suffer from breast cancer
worldwide. Many important problems pertaining to the
oncological details of invasion and metastasis pose sig-
nificant challenges to scientists.
With the development of new techniques in molecular
biology, further exploration into the mechanisms related
to the occurrence of breast cancer have become a hot-
spot in the field of cancer research. The cytokines,
which play regulatory roles in disease development have
become an important topic for many researchers. IL-6,
IL-8, and TNF-a are one group of cytokines produced
by mononuclear macrophages and endotheliocytes
involved in activating and inducing T cells, B cells,
and natural killer cells to target and phagocytosize
pathogenic cells. Additionally, these cytokines are
important factors in inflammation and pathophysiology.
In this study, we monitored the effects of UTI and
TAX, individually and in combination, on the growth of
the negative estrogen receptor (ER-) human breast carci-
noma cell line, MDA-MB-231. Using both cultured cells
in vitro and xenografted tumors in vivo,w ea l s oe x a m -
ined the effects of UTI and TAX on apoptosis and the
expression levels of IL-6, IL-8, and TNF-a cytokines.
Materials and methods
1.1 Cell lines and animals
The human breast cancer cell line MDA-MB-231(ER-)
was a generous gift from the Shanghai Institutes for Bio-
logical Sciences, Chinese Academy of Sciences (CAS).
Fifty female BALB/c-nu/nu nude mice, 5 weeks old and
weighing 17-21 g, were purchased from the Beijing
Institute of Experimental Zoology, CAS, and maintained
in the Chongqing Medical University Animal Research
Center (production license No. SCXK (Jing), 2005-0014,
usage permit No. (Yu), 2007-0001).
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UTI was kindly provided by Techpool Bio-Pharma Co.,
Ltd. TAX was a generous gift from Sanofi-aventis
Pharma Co., Ltd. Maxima™ SYBR Green/ROX qPCR
Master Mix (2X) and RevertAid™ First Strand cDNA
Synthesis Kits was purchased from Fermentas Co. Ltd.,
Canada; Trizol kit was purchased from Invitrogen Co,
Ltd; RT-PCR kit was purchased from NanJing KeyGen
Biotech Co, Ltd. MTT ((3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide), dimethyl sulfoxide
(DMSO), propidium iodide(PI), and phosphate buffered
saline (PBS) were purchased from Sigma Chemical Co.,
Ltd. AMV reverse transcriptase was purchased from
Promega Co, Ltd; RPMI-1640 was purchased from
GIBCO Co., USA. The secondary antibody kit and dia-
minobenzidine (DAB) chromogenic substrate were pur-
chased from Zhongshan Goldenbridge Biotechnology
Co., Ltd. Vascular endothelial growth factor-C (VEGF-
C), basic fibroblast growth factor (bFGF), and nerve
growth factor (NGF) primary antibodies were purchased
from Abcam Co., Ltd., UK.
1.3 Cell cultures and nude mice
MDA-MB-231 cells were cultured in RPMI-1640 med-
ium containing 10% fetal bovine serum (FBS), 100 U/
mL of penicillin, and 100 U/mL of streptomycin at 37°C
in a 5% CO2 atmosphere. Following propagation for 2-3
days, cells in logarithmic growth phase were digested
with 1.0 mL of 0.25% trypsin for 2-3 min, separated
from trypsin, and incubated with double antibody solu-
tion in RPMI-1640 medium containing 10% FBS. Nude
mice were housed in a specific pathogen free (SPF)
environment at 22-25°C and 50-65% relative humidity
with sterile drinking water, food, and experimental
equipment.
1.4 Experimental groups and drug treatments
Cultured MDA-MB-231 cells were divided into four
random groups: Control (RPMI-1640 medium alone),
UTI (8000 U/mL), TAX (3.7 ug/mL; 5 × 10
-6 M), and
UTI+TAX. MDA-MB-231 cells were harvested, rinsed
twice in PBS, resuspended in serum-free RPMI-1640
medium at a density of 2.5 × 10
10 cells/L, and inocu-
lated into the right axillary breast tissue of nude mice
(0.2 mL/mouse × 50 mice). At 21 days post-inoculation,
29 mice with tumors ≥ 500 mm
3 were divided into four
experimental groups: 1) Control (8 mice injected with
PBS); 2) UTI (7 mice injected with 8000 U/mL UTI); 3)
TAX (7 mice injected with 20 mg/kg TAX); and 4) UTI
+TAX (7 mice injected with both UTI and TAX as in
groups 2 and 3). All inoculations were i.p. For groups 1
and 2, 0.2 mL was injected per mouse every day for
20 days. For groups 3 and 4, 20 mg/kg was injected on
days 1, 7, and 14. After 21 days, the mice were sacrificed
for sample preparation. The maximum length (L) and
the minimum diameter (D) of each tumor was measured
using vernier calipers to calculate the tumor volume
(cm
3). Tumor growth curves were constructed and
tumor growth rates were calculated for each experimen-
tal group. We validated the synergistic or antagonistic
effects of the drugs by calculating the q value using
King’s formula. Synergistic, additive, or antagonistic
effects were determined by q > 1.15, 1.15 > q > 0.85,
q < 0.85, respectively. The formulas used were: tumor
volume (cm
3) = (L2 × D)/2; tumor growth inhibition
rate(%) = [1-(V1-V2)/(V3-V4)] × 100%, where V1 and
V2 are the respective starting and ending average tumor
volumes in the drug-treated groups and V3 and V4 are
the respective starting and ending tumor volumes in the
control group; and q = Ea+b/[(Ea+Eb)-Ea × Eb], where
Ea, Eb, (Ea+Eb) represent the inhibitory rates of UTI,
TAX, and UTI+TAX, respectively (King’s formula).
1.5 Quantitation of cell proliferation using the MTT assay
Cells were seeded into 96-well plates at a density of 4 ×
10
3 cells per 200 μL per well. The cells were divided
into four experimental groups (6 wells/group) as
described in 1.4.1 and cultured in RPMI-1640 + 10%
FBS. After 24, 48, and 72 h, 20 μLo f5m g / m LM T T
was added to each well for 4 h. Then 150 μLo fD M S O
was added to each well with shaking for 10 min. The
absorbance (A) at 570 nm was measured using an
enzyme-linked immunosorbant assay (ELISA) plate
reader to quantitate the inhibitory rate. The experiment
was repeated three times. Inhibitory rate (%) =
(1-experimental group A570/control group A570) × 100%
1.6 MDA-MB-231 cell apoptosis
Adherent MDA-MB-231 cells were detached from their
substrates by digestion with 0.125% EDTA-free typsin,
centrifuged for 5 min, resuspended, and rinsed by
centrifugation in PBS at 4°C. The cell pellet was resus-
pended in 490 μL PBS containing 5 μLo fF I T C -
Annexin and 5 μLo f2 5 0u g / m LP Ia n di n c u b a t e do n
ice for 10 min. After two rinses, the cells were analyzed
by flow cytometry using a FACS Vantage SE from
Becton-Dickinson, USA.
1.7 Detection of IL-6, IL-8, and TNF-a mRNA transcripts
by RT-PCR
Based on the complete nucleotide sequences of IL-6, IL-
8, TNF-a, and control gene b-actin supplied by Gen-
Bank, Primer 5.0 software was used by Nanjing Keygen
Biotech Co. Ltd. to design and synthesize primers for
reverse transcriptase-polymerase chain reaction (RT-
PCR). The product lengths for IL-6, IL-8, TNF-a,a n d
b-actin were 84, 160, 108, and 136 base pairs, respec-
tively. The primer pairs used were:
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Page 2 of 7IL-6 sense: 5’ AAATTCGGTACATCCTCGAC 3’,
IL-6 anti-sense: 5’ CCTCTTTGCTGCTTTCACAC 3’,
IL-8 sense: 5’ TACTCCAAACCTTTCCACCC 3’,I L - 8
anti-sense: 5’ AAAACTTCTCCACAACCCTC 3’,
TNF-a sense: 5’ GCCTGCTGCACTTTGGAGTG 3’,
TNF-a anti-sense: 5’ TCGGGGTTCGAGAAGATGAT
3’, b-actin sense: 5’ GCAGAAGGAGATCACAGCCCT
3’,a n db-actin anti-sense:5’ GCTGATCCACATCTGCT
GGAA 3’.
The SYBR Green/ROX qPCR master mix was used
with initial denaturation at 95°C for 5 min followed by:
45 cycles of denaturation at 94°C for 15 s; annealing at
60°C for 30 s; and extension at 55°C for 1 min, and
1 min extension at 95°C. The luminescence signal was
measured during the extension process. The transcritical
cycle (Ct) was analyzed using the PCR apparatus proce-
dure and copy numbers were calculated from 2
-ΔΔCt, the
copy number ratio of expanding target genes and the
internal control gene (b-actin) to determine the mRNA
expression levels of the target genes.
1.8 Detection of IL-6, IL-8, and TNF-a cytokines in
xenografted tumors by immunohistochemistry
Carcinoma tissues were dehydrated using a graded series
from 75, through 80 and 95, to 100% ethanol. Dehy-
drated samples were completely immersed in wax, cut
into 5 μm sections, and mounted on 3-triethoxysilylpro-
pylamine (APES)-treated glass. Sections were treated
with 50 μL non-immune animal serum plus 50 μLo fa
1:50 dilution of anti-IL-6, IL-8, and TNF-a antibodies
for 10 min. PBS was used as a negative control. Primary
antibody incubations were followed by 50 μLo fb i o t i n -
labeled secondary antibody and 50 μL of streptavidin-
peroxidase (SP) solution for 10 min. The sections were
rinsed with PBS three times for 3 min and 100 μLo f
fresh DAB chromogenic substrate solution was added.
Sections were examined microscopically for color devel-
opment for 5-10 min, redyed with hematoxylin (HE), re-
blued with saturated lithium carbonate, dehydrated with
the graded ethanol series (as above), and sealed in neu-
tral gum.
Imaging of all immunohistochemical sections was per-
formed using a Leica microscope electronic imager. The
appearance of tan color or tan particles indicated a posi-
tive reaction in the cells. We performed IOD analysis on
the sections in each group using Image Pro-plus v6.0
software to compare the differences between the group.
1.9 Statistical analysis
All data were analyzed using PASW 18.0 software and
represented as x  s . The variance analysis was adopted
for comparisons between groups. P < 0.05 was consid-
ered to be statistically significant.
Results
2.1 Effects of UTI and TAX on MDA-MB-231 cell
proliferation
Relative to the control group, the growth of MDA-MB-
231 cells treated with UTI, TAX, and UTI+TAX for
24 h was significantly inhibited (P < 0.05; Table 1). The
inhibitory effect increased in a time-dependent manner
when the cells were treated for 48 and 72 h (P < 0.01;
Table 1). The strongest inhibitory effect was produced
by co-treatment with both drugs and the weakest effect
occurred with UTI alone (UTI+TAX > TAX > UTI).
The differences were statistically significant (P < 0.01;
Table 1).
2.2 Effects of UTI and TAX on MDA-MB-231 cell apoptosis
Compared to the control group (1.00), the level of
apoptosis increased to 1.84 for the UTI group, 3.90 for
the TAX group, and 6.79 for the UTI+TAX group
(Table 2).
2.3 Expression of IL-6, IL-8, and TNF-a mRNA in
MDA-MB-231
Treatment of MDA-MB-231 cells with both UTI and TAX
down-regulated the expression of IL-6, IL-8, and TNF-a
transcripts greater than treatment with either UTI or TAX
alone (P < 0.05; Figure 1, Figure 2, Figure 3).
2.4 Effects of UTI and TAX on the growth of ed breast
tumor xenografts
One mouse in the control group died on day 13 and
one mouse in the UTI group died on day 18 due to con-
sumption and cachexia. The 7 tumors in the control
group enlarged in a time-dependent manner, with no
spontaneous tumor deflation or regression. For the
6 mice in the UTI group, the volume of their xeno-
grafted tumors gradually increased at a rate less than
that of the mice in the control group (P < 0.05). For the
7 mice in the TAX group, the volume of their xeno-
grafted tumors also gradually decreased relative to the
controls. For the 7 mice in the UTI+TAX group, the
volume of their tumors decreased with the greatest rate
and extent over time (P < 0.05; Table 3; Figure 4).
2.5 Effects of UTI and TAX on the expression of IL-6, IL-8,
and TNF-a proteins in breast tumor xenografts
Relative to untreated MDA-MB-231 tumor xenografts,
the xenografts from mice treated with UTI, TAX, and
UTI+TAX showed decreased expression of IL-6
(Figure 5, Figure 6), IL-8 (Figure 7, Figure 8), and
TNF-a (Figure 9 Figure 10) proteins. Treatment with
UTI+TAX decreased cytokine expression greater than
treatment with either UTI or TAX alone (P < 0.01;
Figures. 5,6,7,8,9,10).
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Ulinastatin (UTI) is a serine protease inhibitor (SPI)
with extensive inhibitory effects on cell proliferation and
extracellular matrix degradation. Consequently, the pro-
tection of patients in radiotherapy and chemotherapy
becomes an important consideration for researchers.
The experiment of Kobayashi [1] showed that UTI
inhibited human ovarian cancer and the effect could be
related to UTI down-regulation of protein kinase C
(PKC), which regulates the methionine/extracellular-
signal of the MEK/ERK/c-Jun-dependent signal pathway
to collaboratively down-regulate the plasminogen activa-
tor urokinase. The application of UTI and etoposide can
enhance the inhibition of metastasis in Lewis lung carci-
noma (3LL) [2]. Our experiments show that UTI can
inhibit the growth of xenografted breast carcinoma
tumors with the co-application of both UTI and TAX
being most effective.
As one of the core cytokines, interleukin-6 (IL-6), is
produced by lymphocytes, mononuclear cells, fibroblasts,
vascular endothelial cells, and some cancer cells, primar-
ily in autocrine and paracrine secretions. After secretion,
IL-6 combines with the a-subunit of the membrane-
bound IL-6 receptor (IL-6R) and the b-subunit of glyco-
protein 130 (gp 130) for cell signaling. Goswami [3]
used an anti-IL-6 primary antibody to inhibit the prolif-
eration of human glioblastoma multiforme cells, demon-
strating that IL-6 has some effect on promoting tumor
cell proliferation. Burger [4] also reported that cancer
cells and tumor-related macrophages can release high
concentrations of IL-6. Hussein [5] showed that high-
levels of IL-6 indicate poor prognosis and the concen-
tration of IL-6 in the serum of breast cancer patients is
not only elevated, but increases with the clinical stage of
breast cancer. Sasser [6] found that the growth rate of
MCF-7 estrogen-receptor-positive (ER+) breast carci-
noma cells doubled in vitro and increased even more
in vivo following treatment with recombinant human
IL-6. Our results show that UTI inhibits the expression
of IL-6.
Interleukin-8 (IL-8) is produced by monocytes, macro-
phages, T cells, and vascular endothelial cells. UTI
enables neutrophil chemotaxis, defluvium, and lyase
release. Additionally, UTI can protect against inflamma-
tion, promote T cell chemotaxis, and reinforce the
immune response. Heideman [7] suggested that IL-8
promotes leukin chemotaxis into tumors, leading to
tumor neovascularization and the acceleration of tumor
growth and metastasis. IL-8 enters cells by combining
with the chemokine receptor CXCR1, to activate the
extracellular ERK2/1 signaling pathway and promote the
formation of new microvessels. It has been reported that
the expression of IL-8 in breast carcinoma cells is inver-
sely proportional to the level of estrogen receptors (ER).
Based on this relationship, decreased expression of ER
increases the expression of IL-8, leading to increased
tumor deterioration [8]. Our prophase experiment
showed that UTI can inhibit the expression of CXCR4
[9], which is produced by stroma derived factor-1. In
the present study, UTI and TAX inhibited the expres-
sion of IL-8 in xenografted breast tumors in nude mice.
TNF-a is a peptide hormone that affects tumor cell
necrosis, inflammation, and the immune response. The
effects of TNF-a are widespread and mediated through
nearly all of the TNF-a receptors on tumor cells and
many other cells. Gong [10] demonstrated that
increased TNF-a promotes invasion and metastasis in
ductal carcinomas in a scalar fashion. The TNF secreted
by tumor-related macrophages can enhance the invasion
of tumors by increasing the expression of matrix metal-
loproteases (MMPs) in breast carcinoma and vascular
endothelial growth factor (VEGF) in the c-Jun
N-terminal kinase (JNK) and the NF-KB signaling path-
ways [11]. Also, the inflammatory cells of the tumor
microenvironment, consisting primarily of tumor-related
macrophages, can secrete TNF-a continuously to pro-
mote tumor formation, invasion, and metastasis via acti-
vation of protein-1 (AP-1) and the NF-KB pathway [12].
Table 1 Effects of UTI and TAX on the proliferation of human breast cancer MDA-MB-231 cells in vitro (A570, x  s )
24 h 48 h 72 h
Groups A value ( xs  ) Inhibition rate (%) A value ( xs  ) Inhibition rate (%) A value ( xs  ) Inhibition rate (%)
Control 1.086 ± 0.082 0 1.366 ± 0.042 0 1.881 ± 0.106 0
UTI 1.000 ± 0.067
a 7.919 0.867 ± 0.102
a 36.530 0.631 ± 0.067
a 66.454
TAX 0.853 ± 0.051
a,b 21.455 0.703 ± 0.043
a,b 48.536 0.440 ± 0.063
a,b 76.608
UTI+TAX 0.773 ± 0.041
a,b,c 28.821 0.590 ± 0.059
a,b,c 56.808 0.315 ± 0.068
a,b,c 83.254
a P < 0.05 for all treatment groups versus control;
b P < 0.01 for TXT and UTI+TAX groups versus UTI group;
c P < 0.01 for UTI+TAX group versus TAX group.
Table 2 Apoptosis of MDA-MB-231 cells treated with
different drugs
Treatment Apoptotic rate(%) Fold increase
Control 2.52 ± 0.53 0
UTI 7.16 ± 1.59 1.84
TAX 12.35 ± 1.88 3.90
UTI+TAX 19.64 ± 2.26 6.79
Data expressed as mean ± sd. Note: p < 0.05 among different treatments.
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proliferation and invasion of MCF-7 human breast car-
cinoma cells [9] and the growth of MDA-MB-231 (pre-
sent study). Taken together, these effects could be
related to the down-regulation of MMP-9 in breast car-
cinoma cells by UTI [13]. We show here that both UTI
and TAX inhibit the expression of TNF-a.
Ulinastatin (UTI) and docataxel (Taxotere, TAX) inhi-
bit the growth of MDA-MB-231 human breast cancer
cells cultured in vitro and xenografted into nude mice
Figure 1 Effects of UTI and TAX on IL-6 mRNA levels in MDA-
MB-231 cells.
Figure 2 Effects of UTI and TAX on IL-8 mRNA levels in MDA-
MB-231 cells.
Figure 3 Effects of UTI and TAX on TNF-a mRNA levels in
MDA-MB-231 cells.
Table 3 Effects of UTI and TAX on the weight and
restraining rate of breast tumor xenografts in nude mice
Group Sample
size(n)
Mean tumour
volume before
treatment(cm
3)
Mean tumour
volume after
treatment(cm
3)
Mean
tumour
inhibition
(%)
Control 7 0.551 ± 0.026 4.257 ± 0.212 0
UTI 6 0.563 ± 0.012 3.166 ± 0.134 29.312
TAX 7 0.592 ± 0.018 1.106 ± 0.145 86.021
UTI
+TAX
7 0.589 ± 0.021 0.627 ± 0.016 98.264
Figure 4 Effects of UTI and TAX on transplanted breast tumor
size in nude mice.
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Page 5 of 7Figure 5 Effects of UTI and TAX on IL-6 protein expression in
human breast cancer xenografts in immunohistochemistry:
1. Control group SP × 400 2. UTI group SP × 400, 3 TAX group SP ×
400 4. UTI+TAX group SP × 400.
Figure 6 Effects of UTI and TAX on IL-6 protein expression in
human breast cancer xenografts in histogram.
Figure 8 Effects of UTI and TAX on IL-8 protein expression in
human breast cancer xenografts in histogram.
Figure 7 Effects of UTI and TAX on IL-8 protein expression in
human breast cancer xenografts in immunohistochemistry:1 .
Control group SP × 400 2. UTI group SP × 400, 3 TAX group SP ×
400 4. UTI+TAX group SP × 400.
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Page 6 of 7in vivo. The combination of both drugs is stronger than
either drug alone under the conditions tested. The
growth inhibition of human breast carcinoma cells and
tumors could be related to the concomitant down-
regulation of IL-6, IL-8, and TNF-a in breast carcinoma
cells by these drugs.
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Figure 9 Effects of UTI and TAX on of TNF-a protein
expression in human breast cancer xenografts in
immunohistochemistry: 1. Control group SP × 400 2. UTI group SP
× 400, 3 TAX group SP × 400 4. UTI+TAX group SP × 400.
Figure 10 Effects of UTI and TAX on of TNF-a protein
expression in human breast cancer xenografts in histogram.
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